Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Moderate Buy” by Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eighteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $170.41.

SRPT has been the subject of a number of analyst reports. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Piper Sandler dropped their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They set a “hold” rating and a $136.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its stake in Sarepta Therapeutics by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after acquiring an additional 12,000 shares during the period. Geode Capital Management LLC boosted its holdings in Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after buying an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC boosted its stake in Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares during the period. Larson Financial Group LLC boosted its stake in Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Sarepta Therapeutics by 30.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock worth $9,772,000 after buying an additional 18,095 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 1.2 %

SRPT stock opened at $97.19 on Monday. Sarepta Therapeutics has a fifty-two week low of $97.06 and a fifty-two week high of $173.25. The business’s 50-day moving average is $111.73 and its two-hundred day moving average is $119.82. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a market cap of $9.43 billion, a price-to-earnings ratio of 77.75 and a beta of 0.79.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.